TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

Teva Pharmaceutical (TEVA) announced the initiation of IND-enabling studies for BD9, a dual-specific multibody targeting TSLP and IL-13 for TH2-driven inflammatory diseases, sending shares up 4.4% on May 27th, though the stock is still down 19.6% YTD. Separately, the FDA granted Fast Track designation to Teva's TEV-53408, an anti-IL-15 antibody, for celiac disease, as the company progresses its neuroscience and immunology pipeline. Other biotech stocks with a Zacks Rank #2 (Buy), Lexicon Pharmaceuticals (LXRX), Chemomab Therapeutics (CMMB) and Amarin (AMRN), have seen narrowing loss per share estimates for 2025 and 2026.

Analysis

Teva Pharmaceutical Industries (TEVA) demonstrated positive momentum in its drug development pipeline with two key announcements. The initiation of investigational new drug (IND)-enabling studies for BD9, a dual-specific antibody targeting TSLP and IL-13 for inflammatory diseases like asthma and atopic dermatitis, in partnership with Biolojic Design Ltd., spurred a 4.4% increase in TEVA's shares on May 27. BD9, for which Teva holds exclusive global development rights, targets key drivers of TH2-driven inflammation. Separately, Teva's anti-IL-15 antibody, TEV-53408, received Fast Track designation from the FDA for celiac disease, a development intended to expedite its review process, with a Phase IIa study currently underway. These advancements underscore Teva's strategic focus on its neuroscience and immunology pipeline. Despite these positive developments and a Zacks Rank #3 (Hold), Teva's stock has underperformed year-to-date, declining 19.6% compared to the industry's 15.8% fall. In contrast, other biotech firms mentioned, Lexicon Pharmaceuticals (LXRX), Chemomab Therapeutics (CMMB), and Amarin (AMRN), all holding a Zacks Rank #2 (Buy), have seen narrowing loss per share estimates for 2025 and 2026 over the past 60 days. Specifically, LXRX's 2025 loss estimate narrowed from 37 to 32 cents, CMMB's from 70 to 60 cents, and AMRN's from $5.33 to $3.48, with AMRN shares notably gaining 17.1% year-to-date.

Key Decisions for Investors

• Investors should view Teva's recent pipeline advancements, particularly the IND-enabling studies for BD9 and the FDA Fast Track designation for TEV-53408, as positive catalysts, though continued monitoring of clinical trial progress and its impact on the company's financial recovery is warranted given its year-to-date stock underperformance.
• The Fast Track designation for TEV-53408 could significantly shorten the path to market if efficacy is proven, representing a potential upside for Teva's immunology franchise.
• Consider evaluating opportunities in other biotech stocks like LXRX, CMMB, and AMRN, which exhibit improving analyst sentiment as reflected by narrowing loss per share estimates and a Zacks Rank #2 (Buy), suggesting potentially stronger near-term prospects within the sector.